title: Present state of immunosuppressive therapy in liver transplant recipients.
abstract: 1. Our increasing understanding of the signaling pathways and cellular interactions in transplant immunobiology has facilitated targeted strategies using novel immunosuppressive agents. 2. The pattern of immunosuppressive drug use in the United States continues to change, and the changes include the use of antibody induction therapy and the agents used in maintenance therapy. 3. The driving forces behind the development of new immunosuppressive regimens are the long-term complications of current immunosuppressive regimens (particularly renal dysfunction and metabolic disturbances).
authors.affiliation: Transplant Center, Mayo College of Medicine, Rochester, MN 55905, USA. r.wiesner@mayo.edu
authors.forename: Russell H
authors.initials: RH
authors.lastname: Wiesner
authors.forename: John J
authors.initials: JJ
authors.lastname: Fung
mesh_terms: D006084:Graft Rejection / Q000276:immunology* / Q000517:prevention & control*; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods / Q000639:trends*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016031:Liver Transplantation / Q000276:immunology*
chemical_list: D007166:Immunosuppressive Agents